Grant: Master's Award: Canada Graduate Scholarships
University of Calgary
$27,000.00
Exploring Alternative Pathways Driving Inflammation and Gene Expression in Airway Epithelial Cells
FY 2024-25
Summary
Asthma is a chronic inflammatory disease of the airways that affects millions of people annually. While inhaled glucocorticoids (GCs) effectively manage mild-to-moderate asthma, severe asthma is often unresponsive to treatment – representing a significant unmet clinical need. Patients with severe asthma are typically given higher doses of GCs, which increases the risk of side effects despite failure to control symptoms. A key obstacle to addressing this issue is an incomplete understanding of molecular mechanisms underlying airway inflammation. Central to airway inflammation is nuclear factor-kB (NF-kB), a transcription factor which is essential to drive the expression of many, potentially most, inflammatory genes. NF-kB is activated by a cascade of intracellular signalling molecules, known as the NF-kB pathway. While the core NF-kB cascade is well-characterized, there are many components which remain poorly studied. These components may play distinct functional roles, which may shift the understanding of how NF-kB signalling operates. This research aims to address these gaps by using small-molecule inhibitors, gene silencing, and gene deletion to target various NF-kB pathway components. Additionally, next-generation sequencing approaches will be used to identify NF-kB-dependent genes, linking the distinct roles of pathway components to their transcriptional outcomes. Ultimately, an improved understanding of NF-kB signalling may yield additional targets for therapeutic intervention in asthma and other inflammatory conditions.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
530123
Name
Gao Alex
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Exploring Alternative Pathways Driving Inflammation and Gene Expression in Airway Epithelial Cells
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Airway Epithelial Cells; Cytokines; Gene Regulation; Immunology; Inflammation; Kinases; Molecular Biology; Nuclear-Factor Kappa-B (Nf-Kb); Rna Sequencing; Signal Transduction
Abstract
Asthma is a chronic inflammatory disease of the airways that affects millions of people annually. While inhaled glucocorticoids (GCs) effectively manage mild-to-moderate asthma, severe asthma is often unresponsive to treatment – representing a significant unmet clinical need. Patients with severe asthma are typically given higher doses of GCs, which increases the risk of side effects despite failure to control symptoms. A key obstacle to addressing this issue is an incomplete understanding of molecular mechanisms underlying airway inflammation. Central to airway inflammation is nuclear factor-kB (NF-kB), a transcription factor which is essential to drive the expression of many, potentially most, inflammatory genes. NF-kB is activated by a cascade of intracellular signalling molecules, known as the NF-kB pathway. While the core NF-kB cascade is well-characterized, there are many components which remain poorly studied. These components may play distinct functional roles, which may shift the understanding of how NF-kB signalling operates. This research aims to address these gaps by using small-molecule inhibitors, gene silencing, and gene deletion to target various NF-kB pathway components. Additionally, next-generation sequencing approaches will be used to identify NF-kB-dependent genes, linking the distinct roles of pathway components to their transcriptional outcomes. Ultimately, an improved understanding of NF-kB signalling may yield additional targets for therapeutic intervention in asthma and other inflammatory conditions.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Gao, Alex
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~